Say no to Ranbaxy for now: Pro

Considering the FDA ban on drugs manufactured at the company¿s Toansa unit, Nitin Agarwal, Analyst at IDFC Securities, says there are too many risks to buy into Ranbaxy shares. The Indian firm is due to release earnings on Wednesday.